Repare Therapeutics Inc. (RPTX)

Repare Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	97.86	51.13	131.83	7.6	0.14	0
Revenue Growth (YoY)	-28.62%	-61.21%	1634.61%	5529.63%	-	-
Gross Profit	97.86	51.13	131.83	7.6	0.14	0
Selling, General & Admin	33.85	33.76	32.56	26.21	14.35	5.38
Research & Development	134.73	133.59	119.07	90.05	40.09	21
Operating Expenses	168.59	167.36	151.63	116.26	54.44	26.38
Operating Income	-70.73	-116.22	-19.8	-108.66	-54.3	-26.38
Other Expense / Income	-12.66	-13.05	-5.9	-0.07	0.44	0.64
Pretax Income	-58.06	-103.18	-13.9	-108.59	-54.74	-27.02
Income Tax	-12.37	-9.38	15.15	-1.68	-1.33	0.2
Net Income	-45.69	-93.8	-29.05	-106.91	-53.42	-27.22
Shares Outstanding (Basic)	42	42	42	38	20	2
Shares Outstanding (Diluted)	44	42	42	38	20	2
Shares Change	4.72%	0.41%	10.85%	88.66%	1211.56%	-
EPS (Basic)	-1.09	-2.23	-0.69	-2.83	-2.66	-17.81
EPS (Diluted)	-1.10	-2.23	-0.69	-2.83	-2.66	-17.81
Free Cash Flow	-84.9	-129.1	-0.28	-87.45	-8.32	-19.73
Free Cash Flow Per Share	-2.01	-3.07	-0.01	-2.31	-0.41	-12.91
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-72.27%	-227.30%	-15.02%	-1429.74%	-40223.70%	-
Profit Margin	-46.69%	-183.44%	-22.03%	-1406.68%	-39568.15%	-
Free Cash Flow Margin	-86.76%	-252.47%	-0.21%	-1150.61%	-6163.70%	-
EBITDA	-53.84	-99.03	-9.72	-105.24	-52.96	-26.05
EBITDA Margin	-55.01%	-193.68%	-7.37%	-1384.76%	-39225.93%	-
Depreciation & Amortization	4.23	4.15	4.18	3.34	1.79	0.97
EBIT	-58.06	-103.18	-13.9	-108.59	-54.74	-27.02
EBIT Margin	-59.33%	-201.79%	-10.54%	-1428.76%	-40549.63%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).